Experimental drug aims to protect hearts from deadly protein buildup

NCT ID NCT04153149

Ongoing Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether an investigational drug called vutrisiran can help people with a serious heart condition called ATTR amyloidosis with cardiomyopathy. The drug is given as an injection under the skin every three months. Researchers are comparing it to a placebo to see if it reduces deaths, heart-related hospital visits, and improves patients' ability to walk and their quality of life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Clinical Trial Site

La Mesa, California, 91942, United States
Clinical Trial Site

Los Angeles, California, 90033, United States
Clinical Trial Site

Stanford, California, 94305, United States
Clinical Trial Site

Washington D.C., District of Columbia, 20010, United States
Clinical Trial Site

Gainesville, Georgia, 30501, United States
Clinical Trial Site

Chicago, Illinois, 60637, United States
Clinical Trial Site

Evanston, Illinois, 60201, United States
Clinical Trial Site

Boston, Massachusetts, 02115, United States
Clinical Trial Site

Boston, Massachusetts, 02118, United States
Clinical Trial Site

Rochester, Minnesota, 55902, United States
Clinical Trial Site

Manhasset, New York, 11030, United States
Clinical Trial Site

New York, New York, 10032, United States
Clinical Trial Site

Durham, North Carolina, 27710, United States
Clinical Trial Site

Cleveland, Ohio, 44195, United States
Clinical Trial Site

Allentown, Pennsylvania, 18103, United States
Clinical Trial Site

Philadelphia, Pennsylvania, 19104, United States
Clinical Trial Site

Houston, Texas, 77030, United States
Clinical Trial Site

Buenos Aires, Ciudad Autónoma de BuenosAires, C1093AAS, Argentina
Clinical Trial Site

Buenos Aires, Pilar, B1629ODT, Argentina
Clinical Trial Site

Buenos Aires, C1199ABB, Argentina
Clinical Trial Site

Buenos Aires, C1428ART, Argentina
Clinical Trial Site

Darlinghurst, New South Wales, 2010, Australia
Clinical Trial Site

Northmead, New South Wales, 2152, Australia
Clinical Trial Site

Woolloongabba, Queensland, 4102, Australia
Clinical Trial Site

Adelaide, South Australia, 5000, Australia
Clinical Trial Site

Melbourne, Victoria, 3004, Australia
Clinical Trial Site

Graz, 8036, Austria
Clinical Trial Site

Vienna, 1090, Austria
Clinical Trial Site

Vienna, 1210, Austria
Clinical Trial Site

Dendermonde, Oost-Vlaanderen, 9200, Belgium
Clinical Trial Site

Ghent, Oost-Vlaanderen, 9000, Belgium
Clinical Trial Site

Brussels, 1070, Belgium
Clinical Trial Site

Leuven, 3000, Belgium
Clinical Trial Site

Toronto, Ontario, M5G 2C4, Canada
Clinical Trial Site

Québec, Quebec, G1V4G5, Canada
Clinical Trial Site

Zagreb, 10000, Croatia
Clinical Trial Site

Olomouc, Olomoucký kraj, 779 00, Czechia
Clinical Trial Site

Prague, Praha, Hlavní Mesto, 12000, Czechia
Clinical Trial Site

Odense, Region Syddanmark, 5000, Denmark
Clinical Trial Site

Aarhus N, 8200, Denmark
Clinical Trial Site

Créteil, 94000, France
Clinical Trial Site

Marseille, 13385, France
Clinical Trial Site

Paris, 75877, France
Clinical Trial Site

Toulouse, 31059, France
Clinical Trial Site

Frankfurt am Main, Hesse, 60313, Germany
Clinical Trial Site

Leipzig, Saxony, 04103, Germany
Clinical Trial Site

Essen, 45122, Germany
Clinical Trial Site

Göttingen, 37075, Germany
Clinical Trial Site

Heidelberg, 69120, Germany
Clinical Trial Site

Münster, 48149, Germany
Clinical Trial Site

Würzburg, 97078, Germany
Clinical Trial Site

Budapest, 1088, Hungary
Clinical Trial Site

Budapest, 1134, Hungary
Clinical Trial Site

Szeged, 6725, Hungary
Clinical Trial Site

Dublin, D07 A8NN, Ireland
Clinical Trial Site

Dublin, Dublin 8, Ireland
Clinical Trial Site

Haifa, 3339419, Israel
Clinical Trial Site

Jerusalem, 9112000, Israel
Clinical Trial Site

Ramat Gan, 5262000, Israel
Clinical Trial Site

Tsurumai-cho, Aichi-ken, 466-8560, Japan
Clinical Trial Site

Fukuoka, Fukuoka, 810-0001, Japan
Clinical Trial Site

Kurume, Fukuoka, 830-0011, Japan
Clinical Trial Site

Kita-gun, Kagawa-ken, 761-0793, Japan
Clinical Trial Site

Nankoku, Kochi, 783-8505, Japan
Clinical Trial Site

Matsumoto, Nagano, 390-8621, Japan
Clinical Trial Site

Kashihara, Nara, 634-8522, Japan
Clinical Trial Site

Suita, Osaka, 564-8565, Japan
Clinical Trial Site

Suita, Osaka, 565-0871, Japan
Clinical Trial Site

Bunkyo-ku, Tokyo, 113-8431, Japan
Clinical Trial Site

Bunkyo-ku, Tokyo, 113-8655, Japan
Clinical Trial Site

Shinjuku-Ku, Tokyo, 160-8582, Japan
Clinical Trial Site

Fukuoka, 812-8582, Japan
Clinical Trial Site

Kumamoto, 860-8556, Japan
Clinical Trial Site

Riga, LV-1002, Latvia
Clinical Trial Site

Hamra, Beyrouth, 1111, Lebanon
Clinical Trial Site

Kaunas, LT-50161, Lithuania
Clinical Trial Site

Kuantan, Pahang, 25100, Malaysia
Clinical Trial Site

Sungai Buloh, Selangor, 47000, Malaysia
Clinical Trial Site

Chisinau, MD2025, Moldova
Clinical Trial Site

Eindhoven, 5623 EJ, Netherlands
Clinical Trial Site

Groningen, 9713 GZ, Netherlands
Clinical Trial Site

Utrecht, 3584 CW, Netherlands
Clinical Trial Site

Oslo, 0424, Norway
Clinical Trial Site

San Isidro, Lima region, 15076, Peru
Clinical Trial Site

Lima, 15088, Peru
Clinical Trial Site

Wroclaw, Lower Silesian Voivodeship, 50-556, Poland
Clinical Trial Site

Lodz, Lódzkie, 90-127, Poland
Clinical Trial Site

Warsaw, Masovian Voivodeship, 01-192, Poland
Clinical Trial Site

Gdansk, Pomeranian Voivodeship, 80-382, Poland
Clinical Trial Site

Katowice, 40-555, Poland
Clinical Trial Site

Lisbon, Lisbon District, 1649-035, Portugal
Clinical Trial Site

Coimbra, 3000-075, Portugal
Clinical Trial Site

Faro, 8000-386, Portugal
Clinical Trial Site

Guimarães, 4835-044, Portugal
Clinical Trial Site

Porto, 4099-001, Portugal
Clinical Trial Site

Mecca, Mecca Region, 21955, Saudi Arabia
Clinical Trial Site

Riyadh, 12372, Saudi Arabia
Clinical Trial Site

Ljubljana, 1000, Slovenia
Clinical Trial Site

Seoul, 03080, South Korea
Clinical Trial Site

Seoul, 03722, South Korea
Clinical Trial Site

Seoul, 06351, South Korea
Clinical Trial Site

Seoul, 06591, South Korea
Clinical Trial Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Clinical Trial Site

Majadahonda, Madrid, 28222, Spain
Clinical Trial Site

Barcelona, 08035, Spain
Clinical Trial Site

Bilbao, 48013, Spain
Clinical Trial Site

Huelva, 21005, Spain
Clinical Trial Site

Málaga, 29010, Spain
Clinical Trial Site

Göteborg, Västerbotten County, 422 46, Sweden
Clinical Trial Site

Gothenburg, 422 46, Sweden
Clinical Trial Site

Chiang Mai, 50200, Thailand
Clinical Trial Site

Bellshill, Lanarkshire, ML4 3NJ, United Kingdom
Clinical Trial Site

London, London, City of, SE1 1YR, United Kingdom
Clinical Trial Site

Londonderry, Londonderry, BT47 6SB, United Kingdom
Clinical Trial Site

Hexham, Northumberland, NE46 1QJ, United Kingdom
Clinical Trial Site

Birmingham, B15 2SQ, United Kingdom
Clinical Trial Site

Cardiff, CF15 9SS, United Kingdom
Clinical Trial Site

London, NW3 2QG, United Kingdom
Clinical Trial Site

Manchester, M15 6SE, United Kingdom

Conditions

Explore the condition pages connected to this study.

TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY